98 results
6-K
EX-99.1
OBSVF
ObsEva SA
1 Feb 22
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
6:05am
Exhibit 99.1
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA … for women’s health, today announced the appointment of Katja Buhrer as Chief Strategy Officer and member of the company’s Executive Committee, effective
6-K
EX-99.1
OBSVF
ObsEva SA
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
clinical development and medical affairs strategy. She succeeds Dr. Elizabeth Garner, who will be departing the Company on May 6, 2022 to pursue a new … as an advisor to the Company.”
Dr. Howard has deep women’s health expertise with increasing responsibilities in medical affairs strategy
6-K
OBSVF
ObsEva SA
6 Jul 18
Current report (foreign)
7:42am
in the fourth quarter of 2018.
Clear strategy going forward
ObsEva’s strategy is to build the leading women’s reproductive health and pregnancy company … focused on conditions where current treatment options are limited and significant unmet needs exist. The key elements of the strategy include:
Continuing
6-K
EX-99.1
OBSVF
ObsEva SA
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
to initiate a corporate restructuring and refocus the Company’s development and commercialization strategy. ObsEva believes the changes are necessary … the Company’s development and commercialization
strategy, the termination of ObsEva’s license agreement with Kissei, the effects of such termination
6-K
EX-99.1
OBSVF
ObsEva SA
13 Sep 22
ObsEva Announces Progress on Restructuring Initiatives
9:13am
the termination of approximately 70% of employees, including Katja Buhrer, Chief Strategy Officer. The Company expects to substantially complete … of its operations and to refocus the Company’s development and commercialization strategy, including assigning to Kissei additional contracts related
6-K
EX-99.1
uznc876e
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
EX-99.1
omx66psh3 2bv
11 Jan 21
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
7:05am
6-K
EX-99.1
sz21pb6 pr
7 Jul 20
Current report (foreign)
3:39pm
6-K
i755zw1twa7k
7 Jun 17
Current report (foreign)
12:00am
6-K
6wweo 86u
28 Sep 18
Current report (foreign)
8:40am
6-K
EX-99.1
vku ouy4dpdo
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
6-K
EX-99.1
jygv1
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
EX-99.1
oq1bfn3
14 Aug 20
Current report (foreign)
4:24pm
6-K
EX-99.1
fsix 3v264yn
29 Jul 22
ObsEva Announces Management Change
7:06am
6-K
EX-99.2
9z18zpx
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
EX-99.2
o3d8xhk nlje6y
18 Jun 18
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS
9:17am
6-K
EX-99.1
xfwu9wl960t
22 Aug 22
ObsEva Receives Nasdaq Non-Compliance Notice
6:08am
6-K
EX-99.2
yp51itm7 eak6
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.2
kd7xom
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.1
j3ovp ojktw
13 Oct 22
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
7:13am